Advancing therapeutic frontiers in urothelial carcinoma: targeted strategies and clinical implications
Open Access
- 1 December 2024
- journal article
- review article
- Published by AME Publishing Company in Chinese Clinical Oncology
- Vol. 13 (6) , 86
Abstract
Urothelial carcinoma poses significant challenges in clinical management due to its aggressive nature and high prevalence. While most diagnoses involve localized disease, advanced urothelial carcinoma (aUC) often leads to short overall survival (OS). Historically, platinum-based chemotherapy has been the primary treatment for aUC, although its efficacy is limited. However, recent therapeutic advancements, such as immune checkpoint inhibitors (ICIs) and targeted therapy using antibody-drug conjugates (ADCs) and tyrosine kinase inhibitors (TKIs), have shown promise in clinical trials, initially among patients who have undergone platinum-based chemotherapy. Recently, phase III clinical trials have assessed the effectiveness of ICIs, ADCs, and TKIs either in combination or as monotherapy in the first line setting for patients with aUC. As a result of this expanding knowledge, the combination of enfortumab vedotin (EV) with pembrolizumab in the front-line scenario became the new standard of care for aUC, demonstrating significant enhancements in OS and progression-free survival compared to platinum-based chemotherapy. Additionally, other ADCs and targeted therapies have exhibited promising efficacy in clinical trials. This review summarizes recent advancements in the treatment landscape of aUC, focusing on the efficacy and safety profiles of ICIs, ADCs, and TKIs, highlighting the evolving standards and promising combination approaches in the management of this challenging malignancy.Keywords
This publication has 81 references indexed in Scilit:
- Phase II study (KAMELEON) of single‐agent T‐DM1 in patients with HER2‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinomaCancer Medicine, 2023
- An Overview of Angiogenesis in Bladder CancerCurrent Oncology Reports, 2023
- Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-upAnnals of Oncology, 2022
- LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE studyAnnals of Oncology, 2021
- Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and BeyondBioDrugs, 2021
- Molecular markers in bladder cancerWorld Journal of Urology, 2018
- Prognostic Genetic Signatures in Upper Tract Urothelial CarcinomaCurrent Urology Reports, 2016
- HER2 expression status in diverse cancers: review of results from 37,992 patientsCancer and Metastasis Reviews, 2015
- A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinomaCancer, 2014
- A homozygous SLITRK6 nonsense mutation is associated with progressive auditory neuropathy in humansThe Laryngoscope, 2013